Introduction Anti-PD-1/PD-L1 inhibitors therapy has become a promising treatment for
hepatocellular carcinoma (HCC), while the therapeutic efficacy varies significantly among …

Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-
L1) inhibitors have demonstrated commendable efficacy in some patients with advanced …

Background Based on molecular biomarkers, anti-angiogenic drugs in combination with
programmed cell death protein 1 (PD-1) antibodies can screen the potentially beneficial …

Background Immunotherapy has transformed cancer treatment patterns for advanced
hepatocellular carcinoma (aHCC) in recent years. Therefore, the identification of predictive …

Aim: To determine if PD-L1 can be used as a biomarker to predict the efficacy of anti-PD-
1/PD-L1 inhibitors in hepatocellular carcinoma (HCC). Methods: Relevant studies from a …

Background Phosphogluconate dehydrogenase (PGD) is involved in the regulation of
various tumors. However, its role in hepatocellular carcinoma (HCC) is poorly understood …

Purpose. To investigate the prognostic value of blood markers in patients with hepatitis B
virus (HBV)‐induced hepatocellular carcinoma (HCC) treated with PD‐1 inhibitors. Patients …

Background Serum C-reactive protein (CRP) is a biomarker of an acute inflammatory
response and has been successfully used as a prognostic predictor for several …

Simple Summary The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is now
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …

Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading
causes of cancer-related deaths in the world. Mono-immunotherapy and combination …